Trichomonas vaginalis: Treatment questions and challenges

Expert Review of Anti-Infective Therapy

Volumn 10, Issue 2, 2012, Pages 107-109

  Secor, W Evan ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

5 nitroimidazole; drug resistance; Trichomonas vaginalis; trichomoniasis

Indexed keywords

4 NITROIMIDAZOLE; ADENOSINE TRIPHOSPHATE; FURAZOLIDONE; METRONIDAZOLE; MILTEFOSINE; NITAZOXANIDE; PAROMOMYCIN; POVIDONE IODINE; TINIDAZOLE;

ASYMPTOMATIC INFECTION; CRYPTOSPORIDIOSIS; DEVELOPING COUNTRY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG ABSORPTION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; ENZYME SYNTHESIS; GIARDIASIS; HUMAN; INFECTION CONTROL; INFECTION RISK; LOW DRUG DOSE; OXIDATION REDUCTION REACTION; PARASITE TRANSMISSION; PREGNANCY OUTCOME; PUBLIC HEALTH PROBLEM; REVIEW; STEVENS JOHNSON SYNDROME; TRICHOMONAS VAGINALIS; TRICHOMONIASIS; VISCERAL LEISHMANIASIS;

ADMINISTRATION, INTRAVAGINAL; ADULT; ANTI-INFECTIVE AGENTS, LOCAL; ANTIPROTOZOAL AGENTS; DRUG RESISTANCE; FEMALE; HUMANS; METRONIDAZOLE; POVIDONE-IODINE; TINIDAZOLE; TRICHOMONAS INFECTIONS; TRICHOMONAS VAGINALIS;

EID: 84857554187     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.159     Document Type: Review

References (20)

1. Johnston AJ, Mabey DC. Global epidemiology and control of Trichomonas vaginalis. Curr. Opin. Infect. Dis. 21(1), 56-64 (2008).
2. Wendel KA, Workowski KA. Trichomoniasis: challenges to appropriate management. Clin. Infect. Dis. 44(Suppl. 3), S123-S129 (2007).
3. McClelland RS, Sangaré L, Hassan WM et al. Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J. Infect. Dis. 195(5), 698-702 (2007).
4. Van Der Pol B. Trichomonas vaginalis infection: the most prevalent nonviral sexually transmitted infection receives the least public health attention. Clin. Infect. Dis. 44(1), 23-25 (2007).
5. McClelland RJ. Trichomonas vaginalis infection: can we afford to do nothing? J. Infect. Dis. 197(4), 487-489 (2008).
6. Crowell AL, Sanders-Lewis KA, Secor WE. In vitro metronidazole and tinidazole activities against metronidazole-resistant strains of Trichomonas vaginalis. Antimicrob. Agents Chemother. 47(4), 1407-1409 (2003).
7. Hrdý I, Cammack R, Stopka P, Kulda J, Tachezy J. Alternative pathway of mtronidazole activation in Trichomonas vaginalis hydrogenosomes. Antimicrob. Agents Chemother. 49(12), 5033-5036 (2005).
8. Leitsch D, Kolarich D, Duchêne M. The flavin inhibitor diphenyleneiodonium renders Trichomonas vaginalis resistant to metronidazole, inhibits thioredoxin reductase and flavin reductase, and shuts of hydrogenosomal enzymatic pathways. Mol. Biochem. Parasitol. 171(1), 17-24 (2010).
9. Mead JR, Fernadez M, Romagnoli PA, Secor WE. Use of Trichomonas vaginalis clinical isolates to evaluate correlation of gene expression and metronidazole resistance. J. Parasitol. 92(1), 196-199 (2006).
10. Wright JM, Webb RI, O'Donoghue P, Upcroft P, Upcroft JA. Hydrogenosomes of laboratory-induced metronidazole-resistant Trichomonas vaginalis lines are downsized while those from clinically metronidazole-resistant isolates are not. J. Eukaryot. Microbiol. 57(2), 171-176 (2010).
11. Snipes LJ, Gamard PM, Narcisi EM, Beard CB, Lehmann T, Secor WE. Molecular epidemiology of metronidazole resistance in a population of Trichomonas vaginalis clinical isolates. J. Clin. Microbiol. 38(8), 3004-3008 (2000).
12. Bosserman EA, Helms DJ, Mosure DJ, Secor WE, Workowski KA. Utility of antimicrobial susceptibility testing in Trichomonas vaginalis-infected women with clinical treatment failure. Sex. Transm. Dis. 38(10), 983-987 (2011).
13. Helms DJ, Mosure DJ, Secor WE, Workowski KA. Management of Trichomonas vaginalis in women with suspected metronidazole hypersensitivity. Am. J. Obstet. Gynecol. 198(4), 370, e1-e7 (2008).
14. Asensio T, Dávila I, Moreno E et al. Anaphylaxis due to metronidazole with positive skin prick test. J. Invest. Allergol. Clin. Immunol. 18(2), 136-142 (2008).
15. Piskin G, Mekkes JR. Stevens-Johnson syndrome from metronidazole. Contact Dermatitis 55(3), 192-193 (2006).
16. Sutton M, Sternberg M, Koumans EH, McQuillan G, Berman S, Markowitz L. The prevalence of Trichomonas vaginalis infection among reproductive-age women in the United States, 2001-2004. Clin. Infect. Dis. 45(10), 1319-1326 (2007).
17. Crowell AL, Stephens CE, Kumar A, Boykin DW, Secor WE. Activities of dicationic compounds against Trichomonas vaginalis. Antimicrob. Agents Chemother. 48(9), 3602-3605 (2004).
18. Wenzler T, Boykin DW, Ismail MA, Hall JE, Tidwell RR, Brun R. New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289. Antimicrob. Agents Chemother. 53(10), 4185-4192 (2009).
19. Helms DJ, Mosure DJ, Metcalf CA et al. Risk factors for prevalent and incident Trichomonas vaginalis among women attending three sexually transmitted disease clinics. Sex. Transm. Dis. 35(5), 484-488 (2008).
20. Peterman TA, Tian LH, Metcalf CA et al. Persistent, undetected Trichomonas vaginalis infections? Clin. Infect. Dis. 48(2), 259-260 (2009).